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Abstract
Background: Mathematical models of chlamydia transmission can help inform disease control 
policy decisions when direct empirical evaluation of alternatives is impractical. We reviewed 
published chlamydia models to understand the range of approaches used for policy analyses and 
how the studies have responded to developments in the field.
Methods: We performed a literature review by searching Medline and Google Scholar (up to 
October 2015) to identify publications describing dynamic chlamydia transmission models used to 
address public health policy questions. We extracted information on modeling methodology, 
interventions, and key findings.
Results: We identified 47 publications (including two model comparison studies), which 
reported collectively on 29 distinct mathematical models. Nine models were individual-based, and 
20 were deterministic compartmental models. The earliest studies evaluated the benefits of 
national-level screening programs and predicted potentially large benefits from increased 
screening. Subsequent trials and further modeling analyses suggested the impact might have been 
overestimated. Partner notification has been increasingly evaluated in mathematical modeling, 
whereas behavioral interventions have received relatively limited attention.
Conclusions: Our review provides an overview of chlamydia transmission models and gives a 
perspective on how mathematical modeling has responded to increasing empirical evidence and 
addressed policy questions related to prevention of chlamydia infection and sequelae.
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Chlamydia trachomatis is the most commonly reported bacterial sexually transmitted 
infection (STI) in high-income countries.1 Chlamydia prevalence is relatively consistent 
across high-income economies, with 1 study from 6 countries finding pooled prevalence 
estimates for women and men between ages 18 and 26 years at around 4.3% and 3.6%, 
respectively, with minimal heterogeneity across countries.2 Untreated chlamydia infection 
can result in pelvic inflammatory disease (PID) in women, which can lead to ectopic 
pregnancy and tubal factor infertility. Chlamydia can cause epididymitis in men.3,4 The 
association between chlamydia and PID has contributed to an emphasis in prevention efforts 
on screening of young women to prevent sequelae of chlamydial infection.5 The 
introduction of highly sensitive, noninvasive, nucleic acid amplification techniques (NAATs) 
for chlamydia diagnosis has probably also contributed to increases in screening over time.6 
Despite the introduction of public health interventions aimed at detecting and treating 
infections, chlamydia prevalence persists, due in part to existence of a significant 
asymptomatic reservoir.4
For infectious diseases, like chlamydia, mathematical models are often used to examine 
transmission dynamics, synthesize knowledge about natural history and disease outcomes to 
predict future events, and quantify the potential impact of interventions. One use of such 
analyses is to inform policy decisions, especially where there are limited empirical data 
available for comparative evaluation of different interventions.7 For example, mathematical 
models of chlamydia can be used to assess the cost-effectiveness of novel strategies that 
have not yet been deployed on a large scale, such as routine screening of men,8 or to 
estimate risks of PID and long-term reproductive sequelae following infection.9 Some of the 
first mathematical modeling studies of chlamydia were published in 1989 and 1990 by 
Buhaug et al.10,11 These groundbreaking studies used a simulation model of infection and 
progression to consider the potential benefits achieved through screening asymptomatic 
women. In these earliest models, the incidence of infection was defined as an exogenous 
parameter rather than as a dynamic function of the number of infectious individuals in the 
population. An important benefit of the latter approach, which characterizes “dynamic 
transmission models,” is that it allows models to capture both direct effects of interventions 
on infected persons and indirect effects relating to transmission. For this reason, dynamic 
transmission models are recommended when assessing interventions that impact disease 
transmission.12
A number of dynamic transmission models of chlamydia have been developed, and in this 
study, we present a review of the published literature on dynamic transmission models of 
chlamydia that have been used to answer public health and policy questions. We compare 
models in terms of their methodology, interventions considered and key findings. We map 
the models in relation to the accumulating evidence on chlamydia interventions derived from 
clinical trials.
METHODS
Search Strategy
We performed a systematic literature review by searching Medline through PubMed with the 
following search terms: (“transmission dynamics” OR “mathematical model” OR 
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“transmission model” OR “dynamic model” OR “simulation model” OR “computer model” 
OR “cost-effectiveness”) AND chlamydia, without further limits on the search. The search 
terms were selected to reflect the variety in nomenclature around mathematical models of 
infectious diseases. To assure that recent publications and publications not indexed in 
Medline were covered, we performed an additional search in Google Scholar. Google 
Scholar performs a search through the Internet and the full text of the articles. Therefore, we 
used more specific search terms and a shorter time period to limit false positives. We used 
the advanced search function to identify articles with the following words: (“chlamydia 
trachomatis” AND transmission AND dynamic AND “mathematical model”) AND 
(deterministic OR compartmental OR stochastic OR agent OR individual OR network). No 
timeline restrictions were set for PubMed, whereas Google Scholar was limited to after 
1995. In both cases, the end date for inclusion was October 2015.
Figure 1 summarizes the substantive inclusion criteria used in selecting models: we included 
analyses that were based on dynamic transmission models of chlamydia in humans and 
assessed the impact of at least 1 public health intervention. This review did not include in-
host models, static models, or theoretical analyses that did not address a policy question.
Data Analysis
The lead author performed the search, identified the articles and coordinated the data 
extraction, at least 2 people reviewed any extracted material. A mathematical model was 
defined as an “original” in the first publication in which a novel model was described or 
when substantial changes were made to an existing model structure. Original models could 
be applied in subsequent publications, such as decision analysis using outputs from the 
dynamic transmission model, the same model could be reparameterized to a different setting, 
or there could be a variation of the model (minor change in structure or variation in key 
assumptions). Where substantial changes were made to the original model structure, it was 
considered a new model.
For each study, we collected data on modeling framework, natural history assumptions, 
setting and population, intervention (s), outcomes, and conclusions of the study. Whereas we 
are not aware of guidelines for reporting of systematic reviews of modeling studies, we were 
guided by recommendations for good research practice in infectious disease modeling from 
two sources.12,13 Emphasis was given to Pitman et al,12 which focuses on transmission 
models. Our inclusion criteria only included studies using dynamic transmission models, 
which can capture the indirect effects, filling an important criterion for modeling 
interventions against infectious diseases.12 We also measured reporting items to assess 
methodological rigor; specifically, we looked for the presence of differential equations (for 
deterministic compartmental models), or a detailed description of the individual-based 
model (IBM) for model reproducibility. We then evaluated whether the model had been 
calibrated using a statistical or other explicit approach as opposed to ad hoc tuning of the 
model to produce a particular outcome (usually prevalence). Finally, we evaluated whether a 
probabilistic sensitivity analysis had been conducted including key biological and behavioral 
parameters of the model (and not merely analyzing the impact of the intervention at different 
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levels of coverage, for example); an important consideration because there are likely a 
number of parameter combinations that can create any given pattern in the model.
To place the findings of the review within the context of major empirical developments in 
the field, we extracted relevant information from five sources: 3 reviews of clinical trials of 
the effects of chlamydia screening on chlamydia transmission and PID incidence,14–16 a 
review of partner notification (PN) strategies on STI/human immunodeficiency virus 
prevention17 and a more recent randomized clinical trial of the effects of PN on chlamydia 
transmission.18
RESULTS
We found 272 publications through PubMed and 402 articles on Google Scholar. 
Supplementing those searches with the reference lists of the identified articles and applying 
our inclusion criteria led to a final sample of 47,19–29,31s–66s publications in the review, 2 of 
which were model comparison exercises that involved multiple models (supplemental 
references, http://links.lww.com/OLQ/A160). The publications collectively reported on 29 
original dynamic transmission models, summarized in Table S1 (supplemental content, 
http://links.lww.com/OLQ/A158)).
The 2 model comparison exercises by Kretzschmar et al. (2009)65s and Althaus et al. (201 
l)66s were considered as landmark studies, and we organized the results accordingly in 
Figure 2: clinical trials in Figure 2A and the mathematical transmission models identified in 
Figure 2B. Both are ordered by publication year. Because models of chlamydia are informed 
by clinical trials of chlamydia screening and other empirical evidence, we first review major 
advances in the empirical evidence, followed by the chronology of the chlamydia models 
and key measures identified across the studies.
Empirical Evidence Base
Early clinical trials by Scholes et al (1996)67s and Østergaard et al. (2000)68s found a 
halving in PID risk among women 12 months postscreening in comparison to the control 
(usual care) group. In 2010, the prevention of pelvic infection trial reported a nonsignificant 
decrease in relative risk (RR) of PID in those screened (RR, 0.65; 95% confidence interval 
[CI], 0.34–1.22) after 12 months of follow-up.69s The study had low statistical power but a 
more rigorous design than earlier studies (women and clinicians diagnosing PID were 
blinded to the patients’ study arm). Overall, a 2016 Cochrane review of the impact of 
screening for genital chalmydia16 determined there to be a moderate evidence base for 
screening on reduced risk of PID at 12 months post chalmydia test (RR, 0.68; 95% CI, 0.49–
0.94; pooling 4 studies67s–70s).
In contrast, there is limited evidence from trials on the impact of screening on chlamydia 
transmission. Two cluster-randomized trials in high prevalence communities investigated the 
impact of screening on transmission,71s,72s and found a statistically significant reduction in 
positivity in at least one of the groups measured post-screening. The 2016 Cochrane review 
included two randomized trials.73s,74s A nonrandomized cluster Chlamydia Screening 
Implementation (CSI) trial in the Netherlands investigated a population-level active 
Rönn et al. Page 4
Sex Transm Dis. Author manuscript; available in PMC 2019 September 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
screening program. CSI included yearly screening invitations, but screening uptake was low 
and no reduction in chlamydia positivity was observed (RR, 0.96; 95% CI, 0.84–1.09).73s A 
community-randomized trial in urban areas of Peru provided syndromic STI management 
for female sex workers and observed a significant decline in chlamydia positivity over the 
two-year follow-up (RR, 0.72; 95% CI, 0.54–0.98).74s The 2016 Cochrane review 
determined there to be low evidence base to estimate the impact of screening on chlamydia 
prevalence.
Trials of PN on chlamydia transmission18,75s–78s have focused on patient-delivered partner 
therapy (PDPT) in comparison to traditional PN services. Based on a Cochrane 2013 review,
17
 PDPT can be more effective than traditional partner referral at reducing re-infection in 
index cases when “any curable STI” (chlamydia, gonorrhea or trichomonas) is used as the 
outcome measure (RR, 0.71; 95% CI, 0.56–0.89; pooling 6 studies) but no evidence was 
found for chlamydia (RR, 0.90; 95% CI, 0.60–1.35; pooling 2 studies75s,78s). For chlamydia, 
the most encouraging results come from a community randomized clinical trial, which 
suggested that PDPT of the partners of female index cases may decrease ongoing 
transmission of chlamydia at the community level based on positivity in women over time, 
however the prevalence rate ratio was not statistically significant (RR, 0.89; 95% CI, 0.77–
1.04).18
Overview of Models
Models Focusing on Screening Interventions—The earliest dynamic chlamydia 
transmission models focused on the impact of screening interventions. Several models were 
developed for public health agencies to help evaluate the benefits of implementing a 
screening program, such as the Turner55s–57s and Kretzschmar49s,50s models in the United 
Kingdom and the Netherlands, respectively. Low’s model59s,60s was developed as part of an 
economic evaluation of chlamydia screening studies in the United Kingdom. A modeling 
analysis by Townshend,19 for the Department of Health in the United Kingdom, estimated 
opportunistic screening to be cost-saving after 5 years as did a cost-effectiveness analysis for 
the Netherlands based on the Kretzschmar model.51s Both assumed high proportions of the 
population visiting a primary care provider annually, high screening uptake among those 
targeted (eg, women <25 years, varied in model scenarios), and high probability of PID per 
chlamydia infection (25%). A modeling analysis conducted to inform potential screening 
strategies in Australia by Reagan et al.25 suggested screening women and men younger than 
25 years old could reduce chlamydia prevalence by more than 80% with 40% coverage 
maintained over 10 years.
Model comparison exercises65s,66s were motivated by the differences seen in the effects of 
screening interventions predicted by the IBMs of Kretzschmar, Turner and Low.49s,56s,59s In 
the study published in 200965s the impact of a standardized chlamydia screening program 
was compared (35% of sexually active 16- to 24-years-olds were tested for chlamydia, and 
45% of partners were treated; 20% in the Turner model). The models differed in 
assumptions about treatment seeking behavior, levels of testing, and PN occurring before the 
intervention, and these were thought to drive the differences in predicted impact of 
interventions. The combined evidence from the model comparison exercises suggested that 
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screening all sexually active young adults every 2 to 5 years (at coverage, 20–40%) could 
reduce chlamydia prevalence after 5 to 10 years.
The comparison exercises advocated for development of simpler models to promote better 
understanding of the model behavior, combined with exploring parameter uncertainly in 
sensitivity analyses. Studies have since considered the type of model framework chosen 
(individual-based, frequency dependent or pair-formation models),28,38s,39s,44s and the 
effects on transmission dynamics from varying key natural history parameters such as 
duration of infection in asymptomatic persons, and duration of transient immunity,27 where 
the former increases and the latter reduces the estimated impact of a chlamydia screening 
program. Assumptions regarding PID development during infection also affect the impact of 
a screening program (screening is more effective when there is a longer time window for 
screening to detect and treat the infection before sequelae occurs).35s
The increasing empirical evidence and developments in chlamydia modeling are both 
evident in a model by Schmid and colleagues (2013)61s which used Dutch CSI trial data.62s 
Declining participation, as observed in the active screening arm, resulted in less optimistic 
screening predictions in the modeling analysis. The cost-effectiveness ratio estimated for a 
national screening program was unfavorable (comparing screening with existing strategy),62s 
and the evidence contributed to a decision not to implement active chlamydia screening at 
the national level in the Netherlands.
Other Strategies Used—In the modeling studies, screening interventions often included 
PN services, predicting that adding PN to screening would further improve health outcomes. 
PN as an independently beneficial intervention has received increased attention in 
mathematical modeling over the last 10 years.38s,39s,45s,47s,63s Clarke et al.44s suggested that 
partner tracing could provide more value for the money than screening, and Althaus et al. 
(2014)47s found reducing delay to PN (such as in PDPT) would reduce the reinfection rate 
(median reinfection rates, 7.6%, 2.3%, and 0.8% for a delay of 14, 3, and 1 days, 
respectively).
Behavioral interventions and increased condom use have received limited attention in 
chlamydia modeling. Condom use was included in the first Kretzschmar model,49s and in 2 
studies in South Africa.42s,43s In the analyses, increased condom use limited transmission 
and reduced prevalence. Studies that examined interventions in Sub-Saharan Africa also 
examined periodic presumptive treatment and syndromic management, with influence of 
STIs on human immunodeficiency virus transmission as a focal point.41s–43s
By definition, full coverage of a perfectly efficacious vaccine would outperform screening in 
terms of preventing new infections.20 Two models have assessed the potential impact of a 
hypothetical vaccine at different levels of efficacy and coverage.40s,48s Assuming a highly 
efficacious vaccine (efficacy ≥ 75%), vaccination would be a cost-effective addition to 
screening in the United States,40s whilst reducing susceptibility to infection among 
vaccinated individuals would have a greater impact on prevalence than reducing 
infectiousness once infected.48s
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Key Measures Across the Chlamydia Models—Table S2 (supplemental content, 
http://links.lww.com/OLQ/A159) summarizes measures across 45 studies (excluding the 2 
model comparison exercises). Twenty-one publications44s,46s,64s reported on IBMs and 26 
publications19–29,31s–45s included deterministic compartmental models. Among the 26 
publications reporting on deterministic models, the majority (25/26) modeled sexual 
contacts as frequency dependent (assuming instantaneous partnership formation and 
dissolution), and 4 of 26 used a pair formation modeling approach (explicitly modeling 
partnerships and their duration). Four publications included multiple modeling frameworks 
in the same study.28,38s,39s,44s Age and sexual risk behavior are risk factors for chlamydia, 
and 20 of 45 publications included model stratification to capture both of these factors. Less 
than half of all published studies (17/45) assumed natural immunity as part of chlamydia’s 
natural history.
Apart from 3 publications41s–43s that examined Sub-Saharan African settings, all articles in 
this review were set in high-income countries (Fig. 2). The most common settings were the 
United Kingdom (n = 10), the Netherlands (n = 10) and the United States (n = 8). The trials 
identified were conducted in high-income countries except Garcia et al. (2012) in Peru.74s
The most common outcome examined was chlamydia infection (38/45; 84%) followed by 
sequelae (20/45; 44%). Costs were estimated in 21, and 11 considered quality-adjusted life 
years. In comparison, there were 4 trials,71s–74s estimating the impact of screening on 
chlamydia transmission (Fig. 2), of which 2 had sufficient quality to be included in the 2016 
Cochrane review. Six trials67s–70s,79s,80s had measured the impact of screening on PID 
incidence of which 4 were included in the Cochrane review. Half of the modeling studies 
had estimated sequelae outside of the model whilst the others incorporated sequelae directly 
in the model. The latter allows, in theory, more flexibility in exploring the natural history 
and timing of sequelae development.
Twenty-eight publications included PN with or without screening. These suggested 
chlamydia prevention would benefit from increased PN whether traditional or partner-
delivered. The 5 trials identified18,75s–78s give us evidence only of the increased benefit of 
PDPT in comparison to the standard of care (with traditional PN), with unclear evidence on 
the benefits to chlamydia reinfection rates.
We also examined the completeness of reporting in the studies, applying three criteria: 
explicit reporting of model equations or IBM specification, statistical calibration and 
inclusion of sensitivity analyses. Reporting score were calculated for each modeling analysis 
in Table S1 excluding decision analysis studies and the model comparisons. There were 5 
modeling analyses,27,29,32s,41s,55s fulfilling all three of the criteria. Four of these were 
published since 2009, likely reflecting a combination of improvement in reporting of 
transmission models of infectious diseases in general, as well as possibly responding to 
recommendations from the chlamydia model comparison studies. Studies that fulfilled 0 or 1 
of the reporting criteria were published before 2009, with 2 exceptions.
Baseline assumptions about existing interventions are likely to have an influence on the 
relative impact of interventions tested. Most analyses assumed testing of symptomatic cases, 
Rönn et al. Page 7
Sex Transm Dis. Author manuscript; available in PMC 2019 September 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
or did not report baseline assumptions (Table S1). Nine models24,31s,32s,36s,39s,40s,44s,45s,59s 
had 10% or higher screening at baseline before intervention roll-out. Of these, 339s,44s,45s 
concluded that screening linked to PN is an efficacious strategy, 324,31s,32s focused in higher 
risk populations and found targeted screening of core groups to be an effective strategy in 
reducing transmission, whereas 2,36s,59s which examined screening of the general 
population, concluded that screening at levels observed in empirical data was not a cost-
effective strategy compared with baseline level (the remaining analysis investigated a 
hypothetical vaccine together with screening40s).
DISCUSSION
Chlamydia modeling has proliferated since Buhaug’s mathematical models of chlamydia 
screening.10,11 This proliferation is shown in the 47 transmission dynamic modeling studies 
summarized in this review, which date back to Kretzschmar’s first chlamydia transmission 
model in 1996.49s The influence of Kretzschmar’s IBM for chlamydia can be traced not only 
to subsequent analyses using the 200150s version of the model51s,54s but also to models 
developed by Low,59s Turner55s and Schmid61s which have utilized the original framework 
in their respective IBMs.
Based on results from two model comparison studies in 2009 and 2012, we would conclude 
that screening all sexually active young adults every 2 to 5 years (at coverage, 20–40%) 
could reduce chlamydia prevalence after 5 to 10 years. If we relied on evidence from studies 
with the most comprehensive reporting, we would conclude that screening, and periodic 
presumptive treatment, could be effective depending on the setting in question. If we 
assumed the studies with 10% or greater baseline screening before program implementation 
represent a more realistic scenario, we would conclude that the effect of screening comes 
from linked PN, and that targeted screening of higher-risk communities within the 
population is likely beneficial in reducing transmission.
Our review is limited by our broad aim, which led to a variety of outcomes measured in the 
included studies. Sources of variability in the models are difficult to assess in the absence of 
comparable results, which is why model comparison studies with standardized interventions 
across the models may represent the most robust approach in synthesizing modeling 
evidence. Although reporting of the mathematical models has evidently improved, the 
transparency of the analyses could be enhanced by more standardized reporting practices. 
The strength of our review is that we included only transmission dynamic models, which are 
in general better suited to evaluate chlamydia prevention interventions than static models.
Evidence synthesis exercises have helped advance our understanding of the natural history 
of chlamydia and the potential impact of screening on the incidence of PID.81s–83s Recent 
cohort analyses indicate that repeated chlamydia infections may increase the risk of adverse 
reproductive health outcomes.84s,85s Further, theoretical modeling suggests repeat infections 
may help maintain chlamydia at endemic levels.86s Modeling can help to evaluate the 
potential health benefits of strategies to reduce chlamydia reinfection rates, and studies that 
collect data on PID incidence on a routine basis could help to inform such models. Future 
modeling efforts can also be used to inform the development of strategies to increase the 
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yield of chlamydia testing, as opposed to strategies which simply aim to increase the amount 
of testing. We can continue working to improve on screening coverage while also 
investigating the potential benefits of targeting higher risk individuals, improving PN 
strategies and repeated testing for those with a known previous chlamydia infection. 
Empirical studies should aim to measure both positivity and sequelae occurrence to better 
understand the impact of the interventions. Dynamic transmission models can help us 
understand the potential costs and benefits of these interventions.
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Figure 1. 
Algorithm used to select chlamydia transmission models for the review. aDynamic 
transmission models are mathematical models in which transmission is determined 
endogenously. In dynamic models force of infection is defined by the size of the susceptible 
population, prevalence of infection and risks of transmission given contact between infected 
and susceptible persons. bStatic models incorporate a fixed force of infection for a given 
state (such as in Markov Models), whereas dynamic transmission models account for 
underlying population prevalence and infectivity and allow for indirect effects (such as herd 
immunity after vaccination) to be incorporated in the analysis. cTheoretical models are used 
to understand transmission dynamics, but the impact of an intervention at population level is 
not their primary aim.
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Figure 2. 
Timeline of publications forming the evidence base for chlamydia interventions: A, Clinical 
trials of chlamydia. B, The dynamic chlamydia transmission models used to address public 
health questions. Publications are ordered by publication year and are named after the first 
model paper. Figure 2 can be viewed online in color.
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